Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497.

Abstract:

:Small-molecule ligands, amenable to positron emission tomography (PET) imaging of different types of neurodegenerative disease-associated amyloid deposits in the CNS of living patients, hold considerable promise for diagnostic purposes, as well as for monitoring disease progression and the effectiveness of treatments. The patent entitled 'Heterocyclic Compounds as Imaging Probes of Tau Pathology' (WO2013090497) discloses the identification of a novel class of tau imaging agents, the aminothienopyridazines. Selected compounds from this class are described that can stain selectively tau pathology in brain tissue sections. Moreover, examples of this class of compounds exhibit absorption, distribution, metabolism, excretion and pharmacokinetics (ADME-PK) properties that are appropriate for CNS PET ligands.

journal_name

Expert Opin Ther Pat

authors

Ballatore C,Smith AB 3rd,Lee VM,Trojanowski JQ,Brunden KR

doi

10.1517/13543776.2014.871526

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

355-60

issue

3

eissn

1354-3776

issn

1744-7674

journal_volume

24

pub_type

杂志文章
  • Indazole derivatives and their therapeutic applications: a patent review (2013-2017).

    abstract:INTRODUCTION:Indazoles are heterocyclic moieties rarely found in nature. They are nitrogen containing chemical compounds composed of a pyrazole ring condensed with a benzene ring. Various indazole derivatives have been described with a wide variety of biological activities. This has aroused great interest in the develo...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1472240

    authors: Denya I,Malan SF,Joubert J

    更新日期:2018-06-01 00:00:00

  • Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018).

    abstract:INTRODUCTION:Chymase is primarily found in mast cells (MCs), fibroblasts, and vascular endothelial cells. MC chymase is released into the extracellular interstitium in response to inflammatory signals, tissue injury, and cellular stress. Among many functions, chymase is a major extravascular source for angiotensin II (...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1531848

    authors: Ahmad S,Ferrario CM

    更新日期:2018-11-01 00:00:00

  • Research and development of anti-Alzheimer's disease drugs: an update from the perspective of technology flows.

    abstract:INTRODUCTION:Today, over 20 million people suffer from Alzheimer's disease (AD) worldwide. AD has become a critical issue to human health, especially in aging societies, and therefore it is a research hotspot in the global scientific community. The technology flow method differs from traditional reviews generating an i...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1439475

    authors: Liu K,Lin HH,Pi R,Mak S,Han Y,Hu Y

    更新日期:2018-04-01 00:00:00

  • Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.

    abstract:INTRODUCTION:HIV/AIDS is one of the most devastating diseases in the world affecting > 40 million people worldwide. Morbidity and mortality from AIDS are significantly reduced due to the advent of highly active antiretroviral therapy (HAART). Long-term toxicity, emergence of drug resistant HIV strains and drug-drug int...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.542412

    authors: Singh IP,Chauthe SK

    更新日期:2011-02-01 00:00:00

  • Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.

    abstract::In recent years, the involvement of the Hedgehog (Hh) signaling pathway in various human diseases and dysfunctions has been clearly demonstrated. Smoothened (Smo), one of the upstream signal transducers, has been the most druggable target of the Hh pathway. However, the emergence of resistance to Smo inhibitors and th...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2016.1132309

    authors: Manetti F,Petricci E

    更新日期:2016-01-01 00:00:00

  • Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents.

    abstract::In addition to its central role in haemostasis and wound healing, thrombin activates platelets and smooth muscle cells by proteolytic activation of cell surface protease-activated receptor-1 (PAR-1), which is also known as the thrombin receptor. Thrombin is the most potent activator of human platelets and, as such, a ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.16.4.493

    authors: Chackalamannil S,Xia Y

    更新日期:2006-04-01 00:00:00

  • Therapeutic inhibition of the renin angiotensin aldosterone system.

    abstract:BACKGROUND:Inhibitors of the renin angiotensin aldosterone system (RAAS) represent some of the most widely prescribed, successful and well-tolerated therapeutics of recent times and are of proven worth in the management/prevention of cardiovascular disease and diabetic nephropathy. However, as knowledge has grown about...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543770903008536

    authors: Laight DW

    更新日期:2009-06-01 00:00:00

  • Neuropeptide S receptor ligands: a patent review (2005-2016).

    abstract:INTRODUCTION:Neuropeptide S (NPS) is a 20-residue peptide and endogenous ligand of the NPS receptor (NPSR). This receptor was a formerly orphan GPCR whose activation increases calcium and cyclic adenosine monophosphate levels. The NPS/NPSR system is expressed in several brain regions where it controls important biologi...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1254195

    authors: Ruzza C,Calò G,Di Maro S,Pacifico S,Trapella C,Salvadori S,Preti D,Guerrini R

    更新日期:2017-03-01 00:00:00

  • Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.

    abstract:BACKGROUND:Not only hypercholesterolemia, but also low levels of high-density lipoprotein cholesterol is a critical risk factor for atherosclerosis-related disease. Therefore, there has been great interest in identifying effective and selective cholesteryl ester transfer protein (CETP) inhibitors that can raise high-de...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543770903198451

    authors: Shinkai H

    更新日期:2009-09-01 00:00:00

  • Patented small molecule inhibitors of p53-MDM2 interaction.

    abstract::The interaction between p53 and murine double minute 2 (MDM2) provides an attractive drug target in oncology. Small molecule inhibitors of this interaction have not only provided strong evidence for blocking the protein-protein interaction, but are also extremely useful as biological probes and ultimately as novel the...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.16.2.165

    authors: Deng J,Dayam R,Neamati N

    更新日期:2006-02-01 00:00:00

  • Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).

    abstract:INTRODUCTION:The non-receptor tyrosine kinase, inducible tyrosine kinase (Itk), plays an important role in thymus(T)-cell signalling and the production of pro-inflammatory cytokines. Itk, and the other Tec family members, Rlk and Tec, are viewed as attractive drug targets for new agents for the treatment of autoimmune ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.936381

    authors: Norman P

    更新日期:2014-09-01 00:00:00

  • Phosphodiesterase 10 (PDE10) inhibitors: an updated patent review (2014-present).

    abstract::Introduction: Phosphodiesterase 10 (PDE10) is one of at least 11 different PDE families, which are the enzymes that degrade adenosine 3',5'-cyclic monophosphate (cAMP) and/or guanosine 3',5'-cyclic monophosphate (cGMP) by hydrolyzing the phosphodiester bonds. Inhibition of PDE10A represents a molecular target in the t...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2020.1709444

    authors: Zagórska A

    更新日期:2020-02-01 00:00:00

  • Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.

    abstract::Introduction: TIM3 and PD-1 are checkpoint inhibitors in cancer that coordinate the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of TIM3 and PD-1 and consequently improving the immune response in the va...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2019.1637422

    authors: Herrera-Camacho I,Anaya-Ruiz M,Perez-Santos M,Millán-Pérez Peña L,Bandala C,Landeta G

    更新日期:2019-08-01 00:00:00

  • Aldose reductase inhibitors: 2013-present.

    abstract:INTRODUCTION:Aldose reductase (ALR2) is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Accordingly, it represents ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2019.1582646

    authors: Quattrini L,La Motta C

    更新日期:2019-03-01 00:00:00

  • An update on liposomes in drug delivery: a patent review (2014-2018).

    abstract::Introduction: Pharmacotherapy is limited by the inefficient drug targeting of non-healthy cells/tissues. In this pharmacological landscape, liposomes are contributing to the impulse given by Nanotechnology to optimize drug therapy. Areas covered: The analysis of the state-of-the-art in liposomal formulations for drug ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2019.1679767

    authors: El-Hammadi MM,Arias JL

    更新日期:2019-11-01 00:00:00

  • A decade of nutraceutical patents: where are we now in 2018?

    abstract:INTRODUCTION:In the last 10 years, nutraceuticals have grown in interest to researchers, industry, and consumers and are now familiar in the collective imagination as a tool for preventing the onset of a disease. Often nutraceuticals are confused with biologically active phytochemicals/botanicals which can have health ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1552260

    authors: Daliu P,Santini A,Novellino E

    更新日期:2018-12-01 00:00:00

  • Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).

    abstract:INTRODUCTION:Hypoxia-inducible factor (HIF)-1α regulates the expression of genes involved in angiogenesis, cellular energy metabolism, and cell survival during cancer development. The increased expression of HIF-1α in most solid tumors is associated with poor prognoses and therapeutic outcomes. Therefore, HIF has been ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2016.1146252

    authors: Ban HS,Uto Y,Won M,Nakamura H

    更新日期:2016-01-01 00:00:00

  • Small molecule c-Met kinase inhibitors: a review of recent patents.

    abstract:IMPORTANCE OF THE FIELD:c-Met kinase is the receptor for hepatocyte growth factor. Primarily expressed on epithelial and mesenchymal cells its normal function is associated with wound healing, liver regeneration and embryo development. However, dysregulation of c-Met through overexpression, gene amplification, mutation...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543770903514137

    authors: Porter J

    更新日期:2010-02-01 00:00:00

  • Topical composition for treating diabetic cataracts: a patent evaluation (WO2015026380A1).

    abstract::Diabetes mellitus is a major threat to global public health that requires long-term medical attention. In view of the potentially devastating effects of diabetes on ocular health, it highlights the urgent need of therapeutic drugs for the prevention and treatment of the diabetic complications. The patent described in ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2016.1163339

    authors: Hao X,Han Z,Zhu C

    更新日期:2016-06-01 00:00:00

  • Bitopic muscarinic agonists and antagonists and uses thereof: a patent evaluation of US20160136145A1.

    abstract:INTRODUCTION:Bitopic M ligands, that is, ligands that interact both with the ortho- and allosteric binding sites of the M receptor subtypes, hold great potential as novel selective for muscarinic acetylcholine (M) ligands for several therapeutic applications. Areas covered: The patent application describes a set of com...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2017.1272577

    authors: Holzgrabe U,Decker M

    更新日期:2017-02-01 00:00:00

  • Nuclear factor-kappa B inhibitors; a patent review (2006-2010).

    abstract:INTRODUCTION:Nuclear factor (NF)-κB, as transcription factor, is linked to the expression of various genes and plays an essential role in immune and inflammatory responses. Abnormal NF-κB signaling results in human diseases, such as immune disorders, inflammation and various cancers. Therefore, regulation of NF-κB may ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.638285

    authors: Kwak JH,Jung JK,Lee H

    更新日期:2011-12-01 00:00:00

  • Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2012-2015).

    abstract:INTRODUCTION:The activation of leukocytes and the subsequent immune cascade play an essential role in sterile and infectious inflammation. Dysregulation of these immune responses or excess leukocyte activation can induce tissue damage, organ dysfunction and mortality. Formyl peptide receptors (FPRs) are functionally di...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2016.1216546

    authors: Tsai YF,Yang SC,Hwang TL

    更新日期:2016-10-01 00:00:00

  • A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present).

    abstract::Introduction: Discoidin domain receptor 1 (DDR1) is a collagen-activated receptor tyrosine kinase. Upon collagen binding, DDR1 undergoes tyrosine autophosphorylation, which consequently triggers downstream genetic and cellular pathways and plays critical roles in the regulation of cellular morphogenesis, differentiati...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2020.1732925

    authors: Guo J,Zhang Z,Ding K

    更新日期:2020-05-01 00:00:00

  • Bradykinin B1 receptor antagonists: a patent update 2009 - 2012.

    abstract:INTRODUCTION:Due to the role of bradykinin B1 receptor (B1R) in pain and inflammation, B1R antagonists have been suggested as promising drug candidates in chronic pain states. The first disclosed B1R antagonists were peptidomimetics, however, during the last few years, novel chemotypes with improved pharmacodynamic and...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2012.730521

    authors: Bozó É,Éles J,Keserű GM

    更新日期:2012-12-01 00:00:00

  • Global patent landscape of programmed cell death 1: implications of the rapid expansion.

    abstract:INTRODUCTION:Inhibitors of programmed cell death 1 (PD-1) and its ligands are producing a paradigm shift in cancer treatment. The promising clinical outcomes and a multi-billion dollar market have prompted active research and development and resulted in relentless patent protection. However, the global patent landscape...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1378349

    authors: Kong X,Zhang Q,Lai Y,Hu H,Chen X,Hu Y

    更新日期:2018-01-01 00:00:00

  • Tryptase inhibitors: a patent review.

    abstract:INTRODUCTION:Tryptase is one of the main serine-proteinases located in the secretory granules of mast cells, and is released through degranulation, which is involved in the pathogenesis of allergic inflammatory disease, cardiovascular diseases, lung fibrosis and tumor. Therefore, inhibitors targeting tryptase may repre...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1322064

    authors: Ni WW,Cao MD,Huang W,Meng L,Wei JF

    更新日期:2017-08-01 00:00:00

  • Developments around the bioactive diketopiperazines: a patent review.

    abstract:INTRODUCTION:2,5-Diketopiperazines (DKPs) are cyclic dipeptides from two amino acids with or without further structural modifications in DKP nucleus. These DKPs demonstrated attractive bioactive diversity and potential in drug discovery. AREAS COVERED:This review summarized those bioactive DKPs in patents, and provide...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2013.828036

    authors: Wang Y,Wang P,Ma H,Zhu W

    更新日期:2013-11-01 00:00:00

  • Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present).

    abstract::Introduction: The greater interest in TAAR1-mediated potential for the treatment of different pathologies, especially those related to CNS disorders, has given a considerable boost to the search for developing TAAR1-selective small molecules.Areas covered: During the last decade, the medicinal chemistry efforts have a...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2020.1708900

    authors: Tonelli M,Cichero E

    更新日期:2020-02-01 00:00:00

  • Sulfonamide inhibitors: a patent review 2013-present.

    abstract:INTRODUCTION:Sulfonamide compounds are significant class of synthetic bacteriostatic antibiotics still which used today for the therapy of bacterial infections and those caused by other microorganisms. They are also known as sulfa drugs and were the main source of therapy against bacterial infections before the introdu...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1487400

    authors: Gulçin İ,Taslimi P

    更新日期:2018-07-01 00:00:00

  • Novel compound, organic cation transporter 3 detection agent and organic cation transporter 3 activity inhibitor, WO2015002150 A1: a patent evaluation.

    abstract::Increasing pharmacological studies have demonstrated that organic cation transporter 3 (OCT3) plays an important role in controlling the extracellular concentrations of released monoamine neurotransmitter, suggesting that OCT3 might be a promising target in the treatment of depression. As a consequence, compounds show...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2016.1180364

    authors: Hu T,Wang L,Pan X,Qi H

    更新日期:2016-08-01 00:00:00